Search | Clinical Trials Finder

Conditions: Healthy
Interventions: JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Ichthyosis
Interventions: TMB-001, Matching Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 6 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more

Conditions: Acne Vulgaris
Interventions: Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more

Conditions: Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions: PVX-108, Placebo; Biological
Lead sponsor: Aravax Pty Ltd; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more

Conditions: Migraine
Interventions: Galcanezumab, Placebo; Drug · Other
Lead sponsor: Diamond Headache Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ocular Inflammation and Pain After Cataract Surgery
Interventions: APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%; Drug
Lead sponsor: Formosa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 31
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more

Conditions: Dry Mouth Associated With Sjogren's Syndrome, Xerostomia
Interventions: Placebo, 552-02; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 15
States / cities: Trumbull, Connecticut • Gainesville, Florida • Indianapolis, Indiana + 12 more

Conditions: Atopic Dermatitis
Interventions: OPA-15406, Tacrolimus, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more

Conditions: Acne Vulgaris
Interventions: Retin-A Micro 0.04% facial acne treatment, Vehicle control; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years to 11 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Encino, California • San Diego, California • Miami, Florida + 9 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: INO-8875, Placebo; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Psoriasis
Interventions: CD 2027, Calcitriol Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Fridley, Minnesota • Nashville, Tennessee

Conditions: Dry Eye Disease, Dry Eye Syndrome
Interventions: AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more

Conditions: Alzheimer's Disease or Vascular Dementia
Interventions: BAC treatment, Matched vehicle; Drug
Lead sponsor: Charsire Biotechnology Corp.; Industry
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Tempe, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 7 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Ala-Cpn10, Placebo; Biological · Drug
Lead sponsor: Invion, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Chicago, Illinois • Altoona, Pennsylvania + 3 more

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 0
States / cities: Not listed

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: JK07, Matching Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Tucson, Arizona • Stanford, California • Boston, Massachusetts + 4 more

Conditions: Cutaneous Lichen Planus
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more

Conditions: Seborrheic Dermatitis
Interventions: Roflumilast Foam 0.3%, Vehicle foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 22
States / cities: Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more

Conditions: Epidermolysis Bullosa
Interventions: Oleogel-S10, Control gel; Drug
Lead sponsor: Amryt Research Limited; Industry
Eligibility: 21 Days and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Aurora, Colorado • Miami, Florida + 6 more

Conditions: Palmoplantar Pustulosis
Interventions: Delgocitinib cream, Vehicle cream; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Fountain Valley, California • Douglasville, Georgia • West Bloomfield, Michigan + 4 more

Conditions: Delayed Onset Muscle Soreness
Interventions: SST-0225, Placebo; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: South Miami, Florida • Springfield, Missouri

Conditions: Genital Warts, Perianal Warts
Interventions: NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Fountain Valley, California • Lomita, California • San Diego, California + 11 more

Conditions: HCV Infection
Interventions: EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules, Elbasvir Oral Granules; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more

Conditions: Non-segmental Vitiligo
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Hoover, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 24 more

Search by objective public record fields.

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

A Study of Acne Treatment in Children Ages 9 to 11

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia

Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

Quality of Life Study in Adults With Facial Eczema

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)